16 results about "Approved drug" patented technology

The p300 inhibitor specifically regulates the expression of genes that induce fibrosis, thereby acting only on fibrotic tissues and reducing the risk of adverse effects on normal tissues. Because the inhibitor blocks multiple fibrotic signaling pathways, it may be effective for fibrosis in various organs such as the liver, lungs, and kidneys. In addition, by modulating gene expression, the inhibitor has the potential to address the fundamental cause of the fibrotic process. The present invention is characterized in that bronopol is first identified as a specific example of such a p300 inhibitor. In particular, bronopol is an FDA-approved drug with established safety, and therefore is expected to reduce the time and cost required for conducting clinical trials.

Described herein methods of treating urothelial carcinoma with an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor. Also described herein are methods of selling or offering for sale an approved drug product containing a fibroblast growth factor receptor (FGFR) inhibitor.

An intelligent dosing platform system for prior authorization and pharmacy benefit management comprising intelligent injection devices with prior authorization modules configured to receive medication release approval from pharmacies, distributing agents, and payor entities. The system analyzes authorization requirements by evaluating individual payor policies, pharmacy benefit manager formulary restrictions, step therapy requirements, medical necessity criteria, seasonality factors, and timing considerations. An automated decision engine determines authorization approval or denial based on real-time policy evaluation and aggregated device usage data from multiple injection devices. An action coordinator triggers downstream processes including preventing device shipment, updating electronic health records, and coordinating billing system updates. A financial reconciliation module ensures one-to-one correspondence between authorization approvals and fulfillment activities, matching approved medications with actually shipped or administered medications while preventing payment for unapproved medications.

The application discloses application of FTY720 as a PP2A phosphatase activator in preparation of a medicine for treating type I neurofibromatosis. The application first uses FTY720 for treatment of type I neurofibromatosis, and proves that FTY720 significantly inhibits formation of neurofibromas by non-specifically activating PP2A phosphatase. In-vivo experimental results show that FTY720 as a single drug can significantly inhibit tumor growth, and a synergistic effect is presented when FTY720 is combined with a MEK inhibitor, and tumor growth is almost completely inhibited. In-vitro cell experiments show that FTY720 as a single drug or in combination with MEKi treatment can inhibit tumor Schwann cells from forming tumor spheres, inhibit cell proliferation and migration, and induce tumor cell apoptosis. The application overcomes the drug resistance problem existing in the prior art MEK inhibitor, and provides a new treatment strategy for type I neurofibromatosis. FTY720 is an FDA-approved drug, and has good safety and drugability, and has high clinical conversion potential.

The present disclosure provides the first asymmetric total synthesis and target identification of the curcusone natural products. The novel convergent synthesis is built upon a cheap and abundant chiral pool molecule (8) and features a thermal [3,3]-sigmatropic rearrangement and an FeCl3-promoted global hydrolysis / adol condensation cascade to rapidly construct the critical cycloheptadienone core. By performing chemoproteomics with the alkyne probe 37, we identified the previously “undruggable” oncogenic protein BRAT1 as a key cellular target of 1d. Furthermore, 1d inhibits BRAT1 in cancer cells, thereby reducing cancer cell migration, increasing susceptibility to DNA damage, and inducing chemosensitization to the approved drug etoposide. Compound 1d is the first known small-molecule inhibitor for BRAT1, a master regulator of the DDR and DNA repair. Composition matters and methods of uses are within the scope of this disclosure.

This invention relates to the field of biomedicine, specifically to a class of prodrug structures with ROS signal-responsive properties, their preparation methods, and applications. The prodrug molecules with ROS signal-responsive properties developed in this invention can rapidly release bioactive molecules in ROS-rich environments, achieving targeted therapeutic effects. This method has good universality and has been verified to be able to prodrugize various molecules, including four approved drug molecules, improving drug solubility, biocompatibility, reducing cytotoxicity, and enhancing targeted therapeutic effects. Based on the structural characteristics of these molecules, they can also complex with PVA hydrogels to further achieve responsive and controllable drug release.

This invention discloses the application of OXR1 as a target in the preparation of drugs for treating osteoclast-related bone diseases. This invention reveals for the first time the crucial role of OXR1 in osteoclast differentiation: OXR1 directly binds to the KEAP1 protein, promoting the interaction between KEAP1 and p62, thereby mediating mitophagy, clearing excess reactive oxygen species generated during osteoclast differentiation, and maintaining mitochondrial homeostasis. Inhibiting OXR1 expression or function can effectively block osteoclast differentiation and reduce bone loss. Based on this, this invention provides two intervention strategies targeting OXR1: one is gene therapy using adeno-associated viruses carrying shRNA targeting OXR1; the other is screening and validating the novel use of the FDA-approved drug velpatasvir as an OXR1 inhibitor. In vitro and in vivo experiments confirmed that both significantly inhibit osteoclast activity and improve the osteoporotic phenotype in ovariectomized mice.

Acquired hearing loss due to chemotherapy or noise exposure is a major health problem, and Cisplatin chemotherapy often causes permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of Cisplatin- or noise-induced hearing loss. In one aspect, use of Niclosamide, Ingenol, and Elesclomol as an active agent to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and / or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The invention discloses an application of domperidone in preparation of a pharmaceutical preparation for treating inflammatory skin diseases. The domperidone disclosed by the invention can be used as an active ingredient for inhibiting the P2Y14 receptor and is applied to preparation of the medicine for treating the inflammatory dermatitis, a new application of the domperidone is developed, and a new choice is provided for treatment of psoriasis and atopic dermatitis. The domperidone disclosed by the invention has good P2Y14 receptor inhibition activity, and the domperidone has no obvious influence on cell activity under the dosage of 15 mu M; after domperidone intragastric administration is carried out on a mouse with psoriasis and atopic dermatitis, the skin thickness is remarkably reduced, and inflammatory cell infiltration is relieved. According to the application, the effect of domperidone on improving inflammatory skin diseases (psoriasis and atopic dermatitis) by inhibiting P2Y14 receptors is found and verified for the first time through in-vivo and in-vitro experiments, the domperidone has the potential of preparing novel anti-inflammatory drugs, and meanwhile, the domperidone is low in clinical application risk as an FDA approved marketing drug.

This invention belongs to the field of molecular biology and drug screening technology, and provides a method for screening capsaicin targeting SOCS5-RBMX protein interactions and its application. The method involves analyzing the structure of the SOCS5-RBMX protein complex to determine the SOCS5-RBMX binding domain and key binding sites; verifying the inhibitory effect on protein binding through point mutations at these key sites; identifying the binding pocket; using drugs from the ZINC22 small molecule drug database and FDA-approved drugs as ligand molecules, and performing virtual screening with the binding pocket as the docking region to obtain compounds; screening the obtained compounds using AMDET to identify capsaicin as the drug inhibiting SOCS5-RBMX binding; and further screening and verification using capsaicin in in vivo and in vitro experiments. This invention, through the analysis of the SOCS5-RBMX protein complex structure to determine the binding domain and key sites, and then using this as a basis for virtual screening and experimental verification, can accurately screen for drugs inhibiting SOCS5-RBMX binding, improving the accuracy and efficiency of drug screening.

The invention discloses application of luteolin in resisting liver cirrhosis, and belongs to the technical field of new application of medicines. The luteolin is used for resisting liver cirrhosis. In-vivo and in-vitro experiments prove that the luteolin can remarkably improve pathological scores of liver cirrhosis model animals, reduce collagen deposition and restore liver functions, and the effect is definite. The luteolin is a natural source small molecule and has good biocompatibility, and the expected toxic and side effects of the luteolin are smaller than those of an artificially synthesized pathway inhibitor. The invention provides a brand new drug choice for treating liver cirrhosis, finds that luteolin has a remarkable anti-liver cirrhosis effect for the first time, provides a brand new candidate compound which is clear in structure, natural in source and extremely high in development potential for the field of liver cirrhosis without first-line approved drugs at present, and meets the urgent demand of clinical treatment.

The invention relates to application of diosmin in preparation of a medicine for improving emotional symptoms of an IBS (Irritable Bowel Syndrome) patient. According to the application, the application range of the medicine diosmin which has been clinically approved and is suitable for treating various symptoms related to vein lymphatic insufficiency and various symptoms related to acute hemorrhoid attack is expanded to treatment of emotional symptoms of IBS patients for the first time; specifically, the invention provides a new application of diosmin in preparation of medicines for improving the emotional symptoms of IBS patients, breakthrough transformation of new use of old medicines is realized, and strict animal model experiments prove that diosmin can effectively improve the emotional symptoms of IBS model mice and IBS patients. Besides, as a clinically approved medicine, the safety, pharmacokinetics and dosage range of diosmin in a human body are fully verified, so that a solid foundation is provided for the diosmin to quickly enter a clinical test stage of emotional symptoms of IBS patients, the research and development period is remarkably shortened, and the transformation risk is reduced.

The invention relates to the technical field of medicines, in particular to application of Tilbanibulin in preparation of a medicine for treating chikungunya virus (CHIKV) infection. The medicine for resisting CHIKV infection is a medicine composition which takes the tetra-brulin as a unique active ingredient or contains the tetra-brulin, and the medicine for resisting CHIKV infection refers to a medicine for preventing or treating CHIKV infection. Candidate small molecule drugs capable of inhibiting CHIKV infection are screened from a clinically approved drug small molecule library by using an experimental operation system of CHIKV susceptible cells, and the screened tebusbulin can effectively reduce the death rate of mice infected with lethal CHIKV, can be used as a candidate anti-CHIKV drug and has application prospects.

Acquired hearing loss due to chemotherapy or noise exposure is a major health problem and cisplatin chemotherapy often results in permanent hearing loss in cancer patients. However, there are no FDA-approved drugs for the treatment or prevention of cisplatin- or noise-induced hearing loss. In one aspect, the use of niclosamide, murolic acid, and ilesidomine as active agents to treat and prevent hearing impairment, and methods of using the compositions to treat and / or prevent hearing impairment or disorders are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to limit the present application.

The present invention provides methods of treating anemia in a patient in need thereof, comprising administering to the patient in need thereof an effective amount of formoterol or a pharmaceutically acceptable salt thereof (e.g., formoterol fumarate or arformoterol tartrate). The formoterol or a pharmaceutically acceptable salt thereof (e.g., formoterol fumarate or arformoterol tartrate) may be administered conjointly with an erythropoiesis-stimulating agent, optionally wherein the anemia is refractory to the erythropoiesis-stimulating agent. The present invention further provides methods of promoting differentiation of an erythroid progenitor cell toward a mature red blood cell in a patient in need thereof, comprising administering an effective amount of formoterol or a pharmaceutically acceptable salt thereof (e.g., formoterol fumarate or arformoterol tartrate). The formoterol or a pharmaceutically acceptable salt thereof (e.g., formoterol fumarate or arformoterol tartrate) may be administered conjointly with other FDA approved drugs such as luspatercept, lenalidomide, erythropoiesis-stimulating agents (ESAs), including but not limited to epoetin alfa or darbepoetin alfa, and / or a hypomethylating agent, such as azacitidine and / or decitabine.

This invention discloses uses for nicardipine in preparing anti-lung cancer products. This invention provides uses for nicardipine in the preparation of products to treat non-small cell lung cancer. From carrying out cancer drug repositioning for the FDA-and CFDA-approved drug nicardipine, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that nicardipine has a new use as an anti-small cell lung cancer and / or anti-non small cell lung cancer medication, thus achieving a new purpose for an old drug.